ARTICLE | Emerging Company Profile
With crossover funding already in place, Stagliano’s Neuron23 exits stealth with programs in neurology, systemic immune disease
Emerging Company Profile: Westlake Village start-up’s partnership with Germany’s Origenis yields candidates against two targets
December 16, 2020 1:49 PM UTC
After two years in stealth mode, Neuron23 has emerged with $113.5 million in two venture rounds that will support development of programs sourced from a German biotech against two targets implicated in both neurology and immunological disorders.
Led by CEO and board Chair Nancy Stagliano, a biotech veteran who led True North Therapeutics Inc. through its sale to Bioverativ Inc. in 2017, Neuron23 Inc. won the backing of Westlake Village BioPartners — the firm launched in 2018 by Beth Seidenberg and Sean Harper — and Kleiner Perkins in its $33.5 million series A round, then added $80 million in a series B crossover round led by Redmile Group...